Darwin Global Management, Ltd. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001839209
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 9 positions · Total reported value $859.47M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 50.0% · 0 new · 2 cut · 1 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): -16.0% · vs SPY -30.8% · Prev Value $3.77B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2024 13F filing, Darwin Global Management, Ltd. disclosed 9 equity positions with a combined reported value of $859.47M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were CYTK ($246.07M), INSM ($237.08M), PCVX ($163.92M). By sector, the heaviest allocations are Health Care 98.5%, Other 1.5%. Versus the prior quarter, allocation shifted toward Health Care (+33.7pp) and away from Other (-33.7pp).
Versus the prior quarter, Darwin Global Management, Ltd. opened 0 new positions, trimmed 2 and fully exited 1, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 24% of names.
The largest new positions opened in Q2 2024 were CYTK ($246.07M), INSM ($237.08M), GERN ($106.18M).
Of the 1 positions fully exited versus the prior quarter, the largest were NUVL ($107.90M), BHVN ($80.78M), ALPN ($78.57M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- CYTK CYTOKINETICS INC · $246.07M
- INSM INSMED INC · $237.08M
- GERN GERON CORP COM · $106.18M
- CRBP CORBUS PHARMACEUTICALS · $14.27M
- RNAM AVIDITY BIOSCIENCES INC · $8.11M
Fully Exited (vs previous quarter)
- NUVL NUVALENT INC · prev qtr: $107.90M
- BHVN BIOHAVEN LTD · prev qtr: $80.78M
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $78.57M
- BEAM BEAM THERAPEUTICS INC · prev qtr: $70.03M
- APGE APOGEE THERAPEUTICS INC · prev qtr: $55.30M
- XNCR XENCOR INC COM · prev qtr: $24.56M
- TRML TOURMALINE BIO INC · prev qtr: $10.65M
- MRK MERCK & CO INC · prev qtr: $10.50M
Insider Transactions (Form 4)
Latest Darwin Global Management, Ltd. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Darwin Global Management, Ltd. is an SEC-registered 13F filer. As of Q2 2026 it reported 5 US equity positions with a combined value of $3.76B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 5 positions · $3.76B reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: RVMD (REVOLUTION MEDICINES INC) at 54.5%
- Average position size: $752.05M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 3 added, 2 reduced, 1 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.58M | $246.07M | 28.63% | New | |
| 2 |
|
3.54M | $237.08M | 27.58% | New | |
| 3 |
|
2.08M | $163.92M | 19.07% | Reduce | |
| 4 |
|
23.92M | $106.18M | 12.36% | New | |
| 5 |
|
1.53M | $68.77M | 8.00% | Add | |
| 6 |
|
325.14K | $14.27M | 1.66% | New | |
| 7 |
|
452.04K | $10.27M | 1.19% | Reduce | |
| 8 |
|
200.00K | $8.11M | 0.94% | New | |
| 9 |
|
1.92M | $4.81M | 0.56% | Reduce |
FAQ
What did Darwin Global Management, Ltd. buy in 2024-Q2?
In its 2024-Q2 13F filing, Darwin Global Management, Ltd. reported 9 equity positions worth $859.47M in aggregate; its largest disclosed positions were CYTK ($246.07M), INSM ($237.08M), PCVX ($163.92M).
How large is Darwin Global Management, Ltd.'s portfolio?
Darwin Global Management, Ltd. reported $859.47M of long equity holdings across 9 positions as of 2024-Q2. Top-10 holdings account for 100.0% of reported value.
What is Darwin Global Management, Ltd.'s investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.